PathAI\u2019s Best-In-Class Image Management System (IMS) with Advanced AI Analysis and Workflow Capabilities will Complement Roche\u2019s Digital Pathology Portfolio to Drive Laboratory Efficiency
\nCombining Roche\u2019s Strong Position in Companion Diagnostics and PathAI\u2019s Advanced AI Platform Helps Accelerate Clinical Therapy Development, Foster the Discovery of New Biomarkers, and Create Novel Diagnostic Tools
\nThese Integrated Capabilities will Accelerate the Shift from Broad Intervention Toward Personalised Healthcare for Patients<\/p>\n
Roche<\/a> announced today that it has entered into a definitive merger agreement to acquire PathAI<\/a>, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms. Subject to the closing of the transaction, which is expected in the second half of the year, the acquired entity will become part of the Diagnostics division.<\/p>\n This acquisition strengthens Roche\u2019s position in Digital Pathology, which is transforming extensive manual workflows into fully automated, AI-driven processes and insights. Digital pathology enables the creation of high-resolution digital images from physical tissue on slides, allowing pathologists to use AI tools to facilitate diagnostic workflows and provide patients with faster results.<\/p>\n \u201cDigital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better-tailored treatment regimens,\u201d said Matt Sause, CEO at Roche Diagnostics. \u201cBringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.\u201d<\/p>\n Andy Beck, Co-Founder and CEO at PathAI, adds, \u201cJoining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed. Roche\u2019s global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.\u201d<\/p>\n PathAI\u2019s AISight IMS software interface is efficient and user-friendly, seamlessly integrating advanced analysis and workflow capabilities within the digital pathology laboratory. In the rapidly growing pathology market, Roche intends to scale this solution globally.<\/p>\n In addition, the expanded capabilities strengthen Roche\u2019s competitiveness in precision medicine by enhancing its biopharma services. PathAI\u2019s strength in AI-driven solutions, including clinical trial support and translational research, will complement Roche\u2019s deep expertise in companion diagnostics. Combining these capabilities will foster the discovery of new biomarkers, potential drug targets, and novel diagnostic tools, increasing the value Roche can bring to biopharma companies.<\/p>\n About Roche<\/p>\n Roche is a healthcare company uniquely placed to prevent, stop, and cure diseases by uniting leading science and technology across diagnostics, medicines, and digital solutions.<\/p>\n Roche was founded in Basel, Switzerland, in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities, and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases, and immunology with the aim of providing real and positive change for patients, the people they love, and the professionals who care for them.<\/p>\n Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.<\/p>\n